NetScientific PLC (LON:NSCI) said one of its portfolio companies will update the scientific community on an advance in the field of respiratory health.
ProAxsis will give two poster presentations providing further data on its ProteaseTag technology, the company said in a statement on Monday.
READ: Netscienfic up as portfolio company ProAxsis enrols top US hospital to validate respiratory disease tag
The first will cover sputum storage, and specifically the ability to increase in flexibility for transporting patient samples from trial site to lab.
The second will analyse exhaled breath condensate, which NetScientific said increases the range of potential research applications for ProAxsis' NE Immunoassay.
Key conference
The posters will be seen by delegates at the North American Cystic Fibrosis Conference (NACF), taking place from November 1 in Indianapolis.
NetScientific chief executive Francois Martelet said: "We are delighted that ProAxsis' ProteaseTag technology is increasingly utilised in high-impact respiratory health research, indicating its potential to become a leader in the field.
“The findings presented at the highly regarded NACF Conference, demonstrate the clinical relevance of ProAxsis technology."